Peptides for Men and Women Over 50: What the Trials Enrolled

What FDA labels say about older trial participants in approved GLP-1 peptides, including men over 50, and why research-only peptides carry no equivalent age data.

Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

Published September 24, 2026Updated September 30, 2026

The short version

FDA-approved peptide drugs report how many older adults were in their trials, in a label section called Geriatric Use. Research-only peptides have no such section, because none has been through the trials that would produce one. Missing age data is an open question, not an answer either way.

Approved GLP-1 drugs state, by percentage, how many trial patients were 65 and older and 75 and older.
One approved label reports more hip and pelvic fractures in patients 75 and older on drug than on placebo.
Research-only peptides have not been through FDA review, so no age-specific trial data exists for them yet.

A reader searching peptides over 50 wants to know whether the people in these trials looked like them. For a handful of approved peptide drugs, the label answers that directly. For the research-only peptides sold alongside them, there is no label to ask.

The trials report age at 65 and 75, not 50

FDA labelling rules define “geriatric” as 65 and older, and several labels split results again at 75 and older. Nobody in the trial data below was excluded for being in their 50s. They are counted inside the general adult result, not a separate older-adult one. “Over 50” is this page’s framing for a peptide-shopping reader, not a line the label draws. The checkable split starts at 65.

What the approved labels report

Drug (brand)	65+ in trials	75+ in trials	Label’s safety/effectiveness finding
Semaglutide (Wegovy, weight trials)	233 patients (9%) aged 65-74*	23 patients (1%)	No overall difference in effectiveness vs. younger adults
Semaglutide (Wegovy, cardiovascular outcomes trial)	2,656 patients (30%) aged 65-74*	703 patients (8%)	More hip/pelvic fractures on drug than placebo at 75+; more serious adverse reactions at 75+ than in younger adults
Tirzepatide (Mounjaro, seven trials)	1,539 patients (30.1%)	212 patients (4.1%)	No overall differences in safety or effectiveness vs. younger adults
Tirzepatide (Mounjaro, cardiovascular outcomes trial)	3,327 patients (50%)	705 patients (11%)	No overall differences in safety or effectiveness vs. younger adults
Liraglutide (Saxenda)	232 patients (6.9%)	17 patients (0.5%)	No overall differences observed; greater sensitivity in some older individuals not ruled out

Figures are as stated in each drug’s current DailyMed label, section 8.5, Geriatric Use.

* Wegovy’s label reports two separate, non-overlapping bands (65 to 74, and 75 and older) instead of one cumulative 65-and-older figure. Add the two Wegovy columns for the full 65-and-older total: 256 patients (10%) in the weight trials, 3,359 patients (38%) in the cardiovascular outcomes trial. Mounjaro’s and Saxenda’s 65+ figures are already cumulative and include their 75-and-older patients, so they are not directly comparable to the unmarked Wegovy figures without this adjustment.

US legal status - FDA-approved · prescription only

These three are FDA-approved drugs. Their labels exist because their trials were run, reviewed by FDA, and published in a fixed, checkable document - which is the entire reason a geriatric-use figure can be quoted above.

The one finding that isn’t reassuring

Most of the table says the same thing: no overall difference by age. The Wegovy cardiovascular outcomes trial is the exception. Its label states two things:

Patients aged 75 and older reported more hip and pelvic fractures on semaglutide than on placebo.
Patients 75 and older, on drug or placebo, reported more serious adverse reactions overall than younger adults.

That is the label’s own language. It sits in the same section that reports no overall effectiveness difference by age, so both statements are true at once. The sentence needs reading in full, not reducing to “safe at any age.”

Who the labels rule out, and what not to combine these with

Each approved drug’s label answers this in its Contraindications and Drug Interactions sections. All three (Wegovy, Mounjaro, Saxenda) are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. They are also contraindicated after a prior serious hypersensitivity reaction to the drug or its excipients. These exclusions are about thyroid and allergy history, not age, so they apply the same way at 50 as at 75.

On interactions, every label says two things:

Combining any of the three with insulin or a sulfonylurea raises the risk of hypoglycaemia and may call for a lower dose of those other drugs.
All three delay gastric emptying, so each label flags the potential to affect how well other oral medicines are absorbed and recommends monitoring.

Mounjaro’s label is the most specific. It notes that oral contraceptives lose reliability and recommends a non-oral method, or an added barrier method, for four weeks after starting or after each dose increase.

Research-only peptides have no contraindications list or drug-interaction table, because none has gone through the review that produces one.

Research-only peptides: there is no section to read

BPC-157, TB-500, epitalon, MK-677 and the rest of the research-bucket compounds on this site have never completed the FDA trial and review process that produces a Geriatric Use section. There is no label and no section 8.5. No percentage of over-65 or over-75 participants has been published for any of them, because none has run the kind of trial that would generate one.

That does not mean “probably fine” or “no red flags.” It means the evidence this page is about is missing: who a trial enrolled, and what it found by age.

US legal status - Research use only

Research-bucket peptides sold online have not completed FDA review for any human indication. No approved label exists, so no age-stratified safety or effectiveness data has been published for any of them yet.

AU legal status - Not on the ARTG

Not on the Australian Register of Therapeutic Goods, so the TGA has not assessed it for safety, quality or effectiveness. Goods that are not on the ARTG cannot lawfully be supplied or advertised in Australia except through a specific pathway - the Special Access Scheme, an Authorised Prescriber, a clinical trial, or personal importation.

Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.

What this means for a reader over 50

For semaglutide, tirzepatide or liraglutide, check age-specific findings in the label itself, not a summary of it.
For a research-only peptide, there is no equivalent document yet. If a seller suggests otherwise, ask to see it.
An approved drug’s age data does not carry over to a research-only peptide. They are different molecules with separate evidence, and the research peptide’s own age data is still missing.

Common questions

Do peptide trials report the age of participants?

FDA-approved drugs must. Every approved label includes a Geriatric Use section stating what share of trial patients were 65 and older, and whether safety or effectiveness differed by age. Research-only peptides have no approved label and no equivalent requirement.

Is it riskier to take a peptide over 50?

For an approved drug, the label says what its trials found in patients 65 and older. That is the closest a reader gets to a real answer. For a research-only peptide, no age-stratified human data has been published, so risk by age is unknown: not shown to be low, and not shown to be high.

Why do labels split at 65 and 75, not 50?

FDA defines "geriatric" as 65 and older for labelling, and several labels split results again at 75 and older. People in their 50s are reported inside the general adult results, not in a separate older-adult analysis.

What peptide should a 50-year-old man take?

No FDA label names a peptide as the right choice for being 50. The three approved drugs on this page are indicated for specific conditions, such as weight management, not for an age. A prescriber weighs a label's contraindications and interactions against one patient. This page does not recommend a product, and no research-only peptide has a label to check.

What's the best peptide for aging?

None of the peptides on this page is FDA-indicated for aging itself. The three approved drugs are indicated for specific uses, not for age. No research-only peptide has completed a trial that would support an anti-aging claim.

Are peptides good for older skin?

It depends which "peptides" are meant. Topical and oral collagen-type skincare products are a different category from the injectable peptides this page tracks. Neither the FDA-approved drugs above nor any research-only peptide carries an age-specific, trial-backed skin claim.

What is the downside of taking peptides?

For the three approved drugs, the labels say it directly. Each is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Each can delay absorption of other oral medicines. Wegovy's cardiovascular trial reported more hip and pelvic fractures in patients 75 and older on drug than on placebo, and more serious adverse reactions in that age group overall. For research-only peptides, no completed human trial has published a comparable adverse-effect list, so the risk is unknown rather than shown to be mild.

What not to mix with peptides?

For the three approved drugs, each label's drug-interactions section flags two things. Combining with insulin or a sulfonylurea raises hypoglycaemia risk and may need a dose cut. Delayed gastric emptying can affect how well other oral medicines are absorbed. Mounjaro's label adds that oral contraceptive users need a non-oral or added barrier method for four weeks after starting or after each dose increase. No interaction list has been published for research-only peptides, because none has run the trials that would produce one.

What peptide is Jennifer Aniston using?

This site does not report what any named individual uses and cannot verify claims about a specific person's peptide regimen. Peptides marketed for anti-aging in that context are typically unapproved research chemicals such as BPC-157, epitalon and growth-hormone secretagogues like MK-677 and CJC-1295. None is FDA-approved for anti-aging use or has a published age-stratified human trial. Even if a claim about a celebrity were true, it would be one person's experience, not evidence of what a peptide does.

References (3 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.